Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Operating Leases (2019 - 2025)

Neurocrine Biosciences' Operating Leases history spans 7 years, with the latest figure at $471.3 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 3.56% year-over-year to $471.3 million; the TTM value through Dec 2025 reached $471.3 million, up 3.56%, while the annual FY2025 figure was $471.3 million, 3.56% up from the prior year.
  • Operating Leases reached $471.3 million in Q4 2025 per NBIX's latest filing, down from $479.7 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $479.7 million in Q3 2025 to a low of $90.4 million in Q1 2023.
  • Average Operating Leases over 5 years is $222.4 million, with a median of $120.6 million recorded in 2021.
  • Peak YoY movement for Operating Leases: decreased 24.29% in 2023, then surged 218.47% in 2024.
  • A 5-year view of Operating Leases shows it stood at $105.3 million in 2021, then fell by 11.21% to $93.5 million in 2022, then skyrocketed by 102.99% to $189.8 million in 2023, then surged by 139.78% to $455.1 million in 2024, then rose by 3.56% to $471.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Operating Leases are $471.3 million (Q4 2025), $479.7 million (Q3 2025), and $439.1 million (Q2 2025).